Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.